Ascendiant Capital Maintains Buy on HeartSciences, Raises Price Target to $9.2
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and raises the price target from $9 to $9.2.
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and raises the price target from $9 to $9.2.